Lectin-Based Isolation of Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and detecting cancer stem cells in hormone-dependent cancer target organs, such as breast, uterus, prostate, ovaries, endometrium, thyroid, and adrenal glands, are inefficient due to the lack of specific markers and the small size of the cancer stem cell population, leading to late diagnosis and high recurrence rates.
Innovation Solution
The use of lectins like Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I), and Grijfonia simplicifolia lectin II (GSL-II) for labeling and isolating cancer stem cells, allowing for early detection and characterization of cancer stem cells in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used for isolating and detecting cancer stem cells, then the detection process can be performed with existing technology, but the detection precision and reliability are insufficient due to lack of specific markers and small cell population size
Solution Approach 1:
The patent employs lectins as intermediary molecules that specifically bind to glycans on the surface of cancer stem cells. These lectins act as mediators between the detection system and the target cells, enabling specific identification and isolation of cancer stem cells through their unique glycan structures, thereby improving detection precision without requiring complex genetic modifications
Solution Approach 2:
The patent utilizes changes in glycan expression patterns as key parameters to distinguish cancer stem cells from other tumor cells. By detecting specific glycan structures that are differentially expressed on cancer stem cell surfaces, the method transforms the detection approach from protein-marker-based to carbohydrate-marker-based, improving reliability through these distinctive biochemical parameters
2Reliability
If the small population size of cancer stem cells is considered, then the rarity of target cells is acknowledged, but this leads to difficulty in detection and isolation due to insufficient signal strength and high background noise
Solution Approach 1:
The patent extracts and utilizes the unique glycan signatures present on cancer stem cell surfaces as specific detection targets. By focusing on these extracted biochemical features rather than attempting to detect all cellular properties, the method achieves reliable detection of rare cancer stem cells through their distinctive carbohydrate markers, reducing background noise from non-specific signals
Solution Approach 2:
The patent employs lectins conjugated to fluorescent dyes or other detectable labels that produce specific color or fluorescence changes when bound to cancer stem cells. This visual transformation enables easy differentiation of rare cancer stem cells from the background population through their unique glycan-binding properties, significantly improving detection reliability
3Measurement precision
If specific markers for cancer stem cells are developed, then the detection specificity improves, but the development time and complexity of the method increase
Solution Approach 1:
The patent employs lectins that can recognize and bind to specific glycan structures across different types of cancer stem cells from various hormone-dependent organs (breast, prostate, ovarian, uterine cancers). This universal approach allows a single lectin-based methodology to detect multiple cancer stem cell populations, achieving high detection specificity without requiring organ-specific marker development for each cancer type
Solution Approach 2:
The patent utilizes the endogenous glycan structures that are naturally present on the surface of cancer stem cells as their own identification markers. Rather than requiring external introduction of complex protein markers or genetic labels, the method leverages the cells' inherent carbohydrate structures for detection, significantly reducing development time and methodological complexity
4Loss of time
If early detection of cancer stem cells is achieved, then the diagnosis stage is advanced and treatment can be adjusted, but the current lack of specific markers prevents certain discrimination from other tumor cells
Solution Approach 1:
The patent uses lectins as specific intermediary molecules that mediate between the detection system and cancer stem cells through selective glycan binding. This intermediary approach enables early detection by targeting surface carbohydrates that are present and detectable at early disease stages, while simultaneously achieving precise discrimination through the high specificity of lectin-glycan interactions
Solution Approach 2:
The patent shifts the detection parameter from protein markers to carbohydrate markers (glycans) on the cell surface. This parameter change enables early detection because glycan expression patterns are established early in cancer stem cell development, and it provides precise discrimination through the unique glycosylation patterns that distinguish cancer stem cells from other tumor cell populations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables specific and efficient detection and isolation of cancer stem cells, providing early diagnosis and prognostic information, which can help in adjusting treatments to reduce recurrence and improve patient outcomes.
Implementation Method 1
The use of lectins like Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I), and Grijfonia simplicifolia lectin II (GSL-II) for labeling and isolating cancer stem cells
Data Source
AI summary
Disclosed is the in vitro use of at least one lectin for marking cancer stem cells of hormone-dependent cancer target organs, selected from the lectins Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I) and Griffonia simplicifolia lectin II (GSL-II), in particular at least two lectins selected from MAH-II, EEL, PTL-I and GSL-II, in particular the two lectins MAH-II and EEL, in order to obtain cancer stem cells of labeled hormone-dependent cancer target organs in a biological sample.